A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

NCT02849951 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped LT-02 did not appear to help induce remission of UC

Conditions

Ulcerative Colitis

Interventions

DRUG: LT-02
DRUG: LT-02 Placebo

Sponsor

Prometheus Laboratories

Collaborators

[object Object]
[object Object]